{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:07:01Z","timestamp":1787022421040,"version":"build-2736575974"},"reference-count":43,"publisher":"Japan Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0711","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:08:01Z","timestamp":1751652481000},"page":"1099-1114","source":"Crossref","is-referenced-by-count":1,"title":["Balancing efficacy and safety: glucokinase activators in glycemic and metabolic management of type 2 diabetes mellitus\u2014a meta-analysis"],"prefix":"10.1507","volume":"72","author":[{"given":"Yue","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Longchang People\u2019s Hospital, Neijiang 642150, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Longchang People\u2019s Hospital, Neijiang 642150, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Longchang People\u2019s Hospital, Neijiang 642150, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Longchang People\u2019s Hospital, Neijiang 642150, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7178-5050","authenticated-orcid":false,"given":"Jingyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Longchang People\u2019s Hospital, Neijiang 642150, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 American Diabetes Association (2020) Addendum. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 43: 1979.","DOI":"10.2337\/dc20-S009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Teck J (2022) Diabetes-associated comorbidities. Prim Care 49: 275\u2013286.","DOI":"10.1016\/j.pop.2021.11.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Nauck MA, Wefers J, Meier JJ (2021) Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 9: 525\u2013544.","DOI":"10.1016\/S2213-8587(21)00113-3"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Agius L (2009) Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 58: 18\u201320.","DOI":"10.2337\/db08-1470"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6 Toulis KA, Nirantharakumar K, Pourzitaki C, Barnett AH, Tahrani AA (2020) Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs 80: 467\u2013475.","DOI":"10.1007\/s40265-020-01278-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7 Hodson L, Brouwers M (2018) Non-alcoholic fatty liver disease concerns with glucokinase activators. Lancet Diabetes Endocrinol 6: 684\u2013685.","DOI":"10.1016\/S2213-8587(18)30196-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8 Cohen J (2013) Statistical power analysis for the behavioral sciences. Routledge, New York, USA.","DOI":"10.4324\/9780203771587"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9 Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E (2013) Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 15: 923\u2013930.","DOI":"10.1111\/dom.12100"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10 Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E (2013) Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 15: 750\u2013759.","DOI":"10.1111\/dom.12088"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Zhu D, Li X, Ma J, Zeng J, Gan S, et al. (2022) Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28: 965\u2013973.","DOI":"10.1038\/s41591-022-01802-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Yang W, Zhu D, Gan S, Dong X, Su J, et al. (2022) Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28: 974\u2013981.","DOI":"10.1038\/s41591-022-01803-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Zhu D, Gan S, Liu Y, Ma J, Dong X, et al. (2018) Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol 6: 627\u2013636.","DOI":"10.1016\/S2213-8587(18)30105-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14 Amin NB, Aggarwal N, Pall D, Paragh G, Denney WS, et al. (2015) Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab 17: 751\u2013759.","DOI":"10.1111\/dom.12474"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15 Meininger GE, Scott R, Alba M, Shentu Y, Luo E, et al. (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560\u20132566.","DOI":"10.2337\/dc11-1200"},{"key":"15","unstructured":"16 Merck Sharp & Dohme LLC (2015) A study to test MK-0941 in adults with type 2 diabetes mellitus with inadequate glycemic control on insulin (MK-0941-018). https:\/\/clinicaltrials.gov\/study\/NCT00824616 accessed on April 25, 2024."},{"key":"16","doi-asserted-by":"crossref","unstructured":"17 Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, et al. (2019) Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med 11: eaau3441.","DOI":"10.1126\/scitranslmed.aau3441"},{"key":"17","unstructured":"18 Pfizer (2013) Study of safety and efficacy of PF-04991532 in subjects with type 2 diabetes. https:\/\/clinicaltrials.gov\/study\/NCT01338870 accessed on April 25, 2024."},{"key":"18","unstructured":"19 Pfizer (2013) Study of safety and efficacy of PF-04991532 in subjects with type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/study\/NCT01336738 accessed on April 25, 2024."},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Shankar P, Jali M (2025) Standards of care in diabetes-2025. RJMS 15: 4\u20137.","DOI":"10.26463\/rjms.15_1_12"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21 Sternisha SM, Miller BG (2019) Molecular and cellular regulation of human glucokinase. Arch Biochem Biophys 663: 199\u2013213.","DOI":"10.1016\/j.abb.2019.01.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Coghlan M, Leighton B (2008) Glucokinase activators in diabetes management. Expert Opin Investig Drugs 17: 145\u2013167.","DOI":"10.1517\/13543784.17.2.145"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Agius L (2008) Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 414: 1\u201318.","DOI":"10.1042\/BJ20080595"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24 Haeusler RA, Camastra S, Astiarraga B, Nannipieri M, Anselmino M, et al. (2015) Decreased expression of hepatic glucokinase in type 2 diabetes. Mol Metab 4: 222\u2013226.","DOI":"10.1016\/j.molmet.2014.12.007"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Matschinsky FM (2013) GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 34: 90\u201399.","DOI":"10.1016\/j.tips.2012.11.007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, et al. (2021) The simpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care 44: 960\u2013968.","DOI":"10.2337\/figshare.13635230"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27 Chen L ZJ, Yang R, Feng L (2021) Glucokinase activator dorzagliatin (HMS5552) regulates GLP-1 release in T2D patients and is synergistic with sitagliptin and empagliflozin in optimizing beta-cell function. Diabetes 70 (Suppl 1): 117-LB.","DOI":"10.2337\/db21-117-LB"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28 Chow E, Wang K, Lim CKP, Tsoi STF, Fan B, et al. (2023) Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes. Diabetes 72: 299\u2013308.","DOI":"10.2337\/db22-0708"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29 Futamura M, Yao J, Li X, Bergeron R, Tran JL, et al. (2012) Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 1071\u20131080.","DOI":"10.1007\/s00125-011-2439-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30 Oh YS, Lee YJ, Park K, Choi HH, Yoo S, et al. (2014) Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells. Eur J Pharm Sci 51: 137\u2013145.","DOI":"10.1016\/j.ejps.2013.09.005"},{"key":"30","doi-asserted-by":"publisher","unstructured":"31 Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, et al. (2013) Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic \u03b2-cells. Diabetes 62: 3448\u20133458.","DOI":"10.2337\/db13-0052"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32 Zeng J, Gan S, Mi N, Liu Y, Su X, et al. (2023) Diabetes remission in drug-na\u00efve patients with type 2 diabetes after dorzagliatin treatment: a prospective cohort study. Diabetes Obes Metab 25: 2878\u20132887.","DOI":"10.1111\/dom.15179"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33 O\u2019Doherty RM, Lehman DL, T\u00e9l\u00e9maque-Potts S, Newgard CB (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022\u20132027.","DOI":"10.2337\/diabetes.48.10.2022"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34 Zhang Z, Ji G, Li M (2023) Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD. Front Endocrinol (Lausanne) 14: 1247611.","DOI":"10.3389\/fendo.2023.1247611"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35 Agius L (2014) Lessons from glucokinase activators: the problem of declining efficacy. Expert Opin Ther Pat 24: 1155\u20131159.","DOI":"10.1517\/13543776.2014.965680"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36 Berger E, G\u00e9lo\u00ebn A (2022) Insulin prevents fatty acid induced increase of adipocyte size. Adipocyte 11: 510\u2013528.","DOI":"10.1080\/21623945.2022.2107784"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37 Davis EA, Cuesta-Mu\u00f1oz A, Raoul M, Buettger C, Sweet I, et al. (1999) Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 42: 1175\u20131186.","DOI":"10.1007\/s001250051289"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38 Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399\u2013416.","DOI":"10.1038\/nrd2850"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39 Nakamura A, Terauchi Y (2015) Present status of clinical deployment of glucokinase activators. J Diabetes Investig 6: 124\u2013132.","DOI":"10.1111\/jdi.12294"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40 Wu Y, Wang K, Su J, Liu X (2024) Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 103: e36916.","DOI":"10.1097\/MD.0000000000036916"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41 Ren Y, Li L, Wan L, Huang Y, Cao S (2022) Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. J Enzyme Inhib Med Chem 37: 606\u2013615.","DOI":"10.1080\/14756366.2021.2025362"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42 Cavestro C, Rosatello A, Micca G, Ravotto M, Marino MP, et al. (2007) Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? Headache 47: 1436\u20131442.","DOI":"10.1111\/j.1526-4610.2007.00719.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43 Rainero I, Limone P, Ferrero M, Valfr\u00e8 W, Pelissetto C, et al. (2005) Insulin sensitivity is impaired in patients with migraine. Cephalalgia 25: 593\u2013597.","DOI":"10.1111\/j.1468-2982.2005.00928.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44 Islam MR, Nyholt DR (2022) Glucose-related traits and risk of migraine\u2014a potential mechanism and treatment consideration. Genes (Basel) 13: 730.","DOI":"10.3390\/genes13050730"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0711\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:55:45Z","timestamp":1759550145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/10\/72_EJ24-0711\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0711","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0711"}}